Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
ChALSR
Registration Study of Natural History and Clinical Characteristics of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
1 other identifier
observational
4,752
1 country
1
Brief Summary
A multi-center registration study of natural history and clinical characteristics of ALS in mainland China
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 17, 2020
CompletedStudy Start
First participant enrolled
March 20, 2020
CompletedFirst Posted
Study publicly available on registry
March 31, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2023
CompletedApril 28, 2020
March 1, 2020
3 years
March 17, 2020
April 26, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Effective Survival
The length of time from the date of diagnosis to patient death or tracheotomy or ventilator-assisted breathing.
through study completion, an average of 3 month
Secondary Outcomes (5)
Overall Survival
through study completion, an average of 3 month
Rate of disease progression
through study completion, an average of 3 month
Rate of Weight decline
through study completion, an average of 3 month
Rate of BMI decline
through study completion, an average of 3 month
Rate of Forced Vital Capacity (FVC)
through study completion, an average of 3 month
Eligibility Criteria
Patients who meet the criteria will be enrolled from multi-centers in mainland China.
You may qualify if:
- Clinical diagnosis of laboratory-supported probable, probable, or definite ALS according to EI Escorial diagnostic criteria
- Age: 18-70 years
You may not qualify if:
- Refuse to cooperate or reject the informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
Related Publications (1)
He J, Fu JY, Chen L, He J, Dang J, Zou Z, Ma S, Li N, Fan D. Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol. BMJ Open. 2020 Dec 4;10(12):e042603. doi: 10.1136/bmjopen-2020-042603.
PMID: 33277290DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dongsheng Fan, MD, PhD
Peking University Third Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 17, 2020
First Posted
March 31, 2020
Study Start
March 20, 2020
Primary Completion
March 20, 2023
Study Completion
March 20, 2023
Last Updated
April 28, 2020
Record last verified: 2020-03